Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06871176 | PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07009002 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT02285582 | International Rare Histiocytic Disorders Registry (IRHDR)(IRHDR) | recruiting | — | 400 | The Hospital for Sick ChildrenOTHER | 9 | Jun 24, 2025 | clinicaltrials |
| NCT05481502 | An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors(PIONEER) | recruiting | N/A | 160 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05618041 | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | recruiting | N/A | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07032103 | Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV(SMCLYM-IV) | recruiting | — | 2,000 | Samsung Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma(BAH2573) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06785324 | Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)(NEOMA ALL) | recruiting | N/A | 20 | University of ChicagoOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07028970 | Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection | recruiting | — | 1,500 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06550427 | Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing | recruiting | — | 200 | National Taiwan University HospitalOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06607289 | National Longitudinal Cohort of Hematological Diseases (NICHE) - CART | recruiting | — | 1,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06700798 | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial | recruiting | Phase 2 | 90 | Fei LiOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07019766 | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia(NICHE-LGLL) | recruiting | — | 9,999 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07021677 | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"(DARA_T_ALL) | recruiting | Phase 2 | 18 | Tata Memorial CentreOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05253495 | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma(RADICAL) | recruiting | Phase 2 | 80 | New York Medical CollegeOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04687176 | Frontline Oral Arsenic Trioxide for APL | recruiting | Phase 2 | 100 | The University of Hong KongOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | recruiting | Phase 4 | 59 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04417803 | Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques(BIOLYMPH2020) | recruiting | N/A | 1,200 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04957901 | The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study | recruiting | — | 60 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05219721 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 18 | Chunrui LiOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05828628 | CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study(CLIMB) | recruiting | — | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06263361 | Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma. | recruiting | — | 15 | IRCCS San RaffaeleOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014449 | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Hangzhou Weben Pharma Co., LtdINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014943 | High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 34 | Sichuan UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06778187 | Oral-ATO for TP53-mutated Myeloid Malignancies | recruiting | Phase 2 | 30 | The University of Hong KongOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06940960 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | recruiting | Phase 2 | 32 | yuejun LiuOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05541341 | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | recruiting | — | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06717113 | A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma | recruiting | Early Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07007949 | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia | recruiting | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06119269 | Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase(PHOENICS) | recruiting | — | 100 | University of PisaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06414148 | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma(EpLCART) | recruiting | Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06793410 | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06987916 | Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06130579 | Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT | recruiting | Phase 2 | 35 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06390306 | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | recruiting | — | 30 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06880354 | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000617 | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma | recruiting | Phase 2 | 57 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07002099 | Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study | recruiting | Phase 2 | 26 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05036564 | Diagnosis; Objective RespOnse; THErApy(DOROTHEA) | recruiting | N/A | 70 | IRCCS San RaffaeleOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06999031 | A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06999954 | Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform(SDS-GPS) | recruiting | — | 8,000 | Shwachman-Diamond Syndrome Alliance IncOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | recruiting | Phase 1 / Phase 2 | 29 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jun 25, 2025source: clinicaltrials